To appraise the clinical and cost-effectiveness of ADI-PEG 20 in combination with pemetrexed and cisplatin within its marketing authorisation for mesothelioma
- Status:
- Awaiting development
- Technology type:
- Medicine
- Decision:
- None selected
- Process:
- STA Standard
- ID number:
- 1575
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 09 April 2024 | Awaiting development. Following on from advice received from the company, timelines for this appraisal are to be confirmed whilst the company confirm their regulatory filing plans. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 01 March 2024 | Note - Note added to the project documents |
| 08 May 2019 | In progress. Referred 17 October 2018 |
For further information on our processes and methods, please see our CHTE processes and methods manual